Core Viewpoint - Elastic (ESTC) shares have shown a slight increase of 0.2% over the past month, closing at $86.07, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $118.33, representing a 37.5% upside [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of 24 short-term price targets with a standard deviation of $15.52, where the lowest estimate is $90.00 (4.6% increase) and the highest is $150.00 (74.3% increase) [2]. - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about ESTC's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11]. - The Zacks Consensus Estimate for the current year has risen by 27.5% over the past month, with six estimates increasing and no negative revisions [12]. - ESTC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside [13]. Caution on Price Targets - While consensus price targets are a popular metric, relying solely on them for investment decisions may not be prudent due to historical concerns about analysts' biases and inflated targets [3][8][10].

Core Viewpoint - Castle Biosciences, Inc. (CSTL) shows potential for significant upside, with a mean price target of $35.63 indicating a 50.1% increase from the current price of $23.74 [1] Price Targets - The average price target consists of eight estimates ranging from $30.00 to $41.00, with a standard deviation of $3.54, suggesting a consensus among analysts [2] - The lowest estimate indicates a 26.4% increase, while the highest suggests a 72.7% upside [2] - A low standard deviation indicates a high degree of agreement among analysts regarding price movement [9] Analyst Sentiment - Analysts have shown increasing optimism about CSTL's earnings prospects, with a strong agreement in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, one estimate has increased, leading to a 1.5% rise in the Zacks Consensus Estimate [12] Zacks Rank - CSTL holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for near-term upside [13] Conclusion on Price Movement - While the consensus price target may not reliably indicate the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - Knightscope, Inc. (KSCP) shows significant upside potential with a mean price target of $15.67, indicating a 170.2% increase from the current trading price of $5.8 [1] Price Targets and Estimates - The mean estimate consists of three short-term price targets with a standard deviation of $10.02, where the lowest estimate is $8.00 (37.9% increase) and the highest is $27.00 (365.5% increase) [2] - A low standard deviation among price targets suggests a strong agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts exhibit growing optimism about KSCP's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 3.5% over the past month, with one estimate increasing and no negative revisions [12] - KSCP holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, and reliance solely on them may not yield favorable returns [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Disc Medicine, Inc. (IRON) has shown a significant price increase of 38.6% over the past four weeks, with a mean price target of $108.82 indicating a potential upside of 26.3% from the current trading price of $86.17 [1] Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $18.55, suggesting variability in analyst predictions. The lowest estimate is $86.00 (0.2% decline), while the highest is $153.00 (77.6% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement direction and magnitude [9] Earnings Estimates and Analyst Sentiment - Analysts are optimistic about IRON's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.3%, with one estimate moving higher and no negative revisions [12] - IRON holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting strong potential for near-term upside [13] Caution on Price Targets - While consensus price targets are often sought after, they can mislead investors, as empirical research shows that they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Teva Pharmaceutical Industries Ltd. (TEVA) shows potential for significant upside, with a mean price target of $24.88 indicating a 28.1% increase from its current price of $19.42 [1][11]. Price Targets - The average price target consists of eight estimates ranging from a low of $20.00 to a high of $29.00, with a standard deviation of $2.53, suggesting a consensus among analysts [2]. - The lowest estimate indicates a 3% increase, while the highest suggests a 49.3% upside [2]. Analyst Sentiment - Analysts have shown increasing optimism regarding TEVA's earnings prospects, as evidenced by a trend of upward revisions in earnings estimates [11]. - The Zacks Consensus Estimate for the current year has increased by 0.8%, with two estimates moving higher and one lower over the past 30 days [12]. Zacks Rank - TEVA holds a Zacks Rank of 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13]. Price Movement Implications - While the consensus price target may not be a reliable predictor of the exact price movement, the direction it implies appears to be a useful guide for potential stock performance [14].

Core Viewpoint - Liquidia Technologies, Inc. (LQDA) has seen a 6.7% increase in share price over the past four weeks, closing at $24.44, with a potential upside of 50.9% based on Wall Street analysts' mean price target of $36.89 [1][11]. Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $13.63, indicating variability among analysts [2]. - The lowest estimate is $6.00, suggesting a 75.5% decline from the current price, while the highest estimate is $54.00, indicating a potential surge of 121% [2]. - A low standard deviation signifies a strong agreement among analysts regarding the stock's price movement direction [9]. Earnings Estimates and Analyst Sentiment - Analysts show strong agreement in revising earnings estimates upward, which correlates with potential stock price increases [11]. - Over the past 30 days, one estimate has increased, leading to a 1.9% rise in the Zacks Consensus Estimate for the current year [12]. - LQDA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13]. Caution on Price Targets - While price targets are commonly referenced by investors, they can often mislead and should not be the sole basis for investment decisions [7][10]. - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8].

Core Viewpoint - Serve Robotics Inc. (SERV) shares have increased by 2.5% over the past four weeks, closing at $14.33, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $18.67, representing a 30.3% increase [1] Price Targets and Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $4.37, where the lowest estimate is $15.00 (4.7% increase) and the highest is $26.00 (81.4% increase) [2] - A low standard deviation indicates a higher agreement among analysts regarding price movement, suggesting a more reliable consensus [2][9] Analyst Sentiment and Earnings Estimates - Analysts are optimistic about SERV's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - Over the last 30 days, one earnings estimate has increased, leading to a 0.5% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - SERV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] - While consensus price targets may not be entirely reliable, the direction they imply appears to be a useful guide for potential price movement [14]

Core Viewpoint - Unusual Machines, Inc. (UMAC) has shown a significant price increase of 14.8% over the past four weeks, with a mean price target of $17.75 indicating a potential upside of 39.2% from the current price of $12.75 [1] Price Targets and Analyst Consensus - The average price target for UMAC ranges from a low of $10.00 to a high of $25.00, with a standard deviation of $6.34, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 21.6%, while the highest points to a potential upside of 96.1% [2] - Analysts' price targets should be approached with caution, as they may not accurately reflect future stock prices due to potential biases [3][7] Earnings Estimates and Analyst Agreement - Analysts have shown strong agreement in revising UMAC's earnings estimates upward, which is a positive indicator for potential stock price increases [4][11] - Over the past 30 days, one estimate has increased, leading to a 60.3% rise in the Zacks Consensus Estimate for the current year [12] - UMAC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of UMAC's potential gains, the direction indicated by the price movement appears to be a useful guide for investors [14]

Core Viewpoint - Enovix Corporation (ENVX) shows significant potential for upside, with a mean price target of $20.89 indicating an 81.5% increase from its current trading price of $11.51 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $6.09, suggesting variability in analyst predictions [2] - The lowest estimate is $12.00, indicating a 4.3% increase, while the highest estimate is $30.00, suggesting a potential surge of 160.6% [2] - A low standard deviation among price targets indicates strong agreement among analysts regarding the stock's price direction [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about ENVX's earnings prospects, with a positive trend in earnings estimate revisions [11] - Over the last 30 days, one estimate has increased, leading to a 1.5% rise in the Zacks Consensus Estimate [12] - ENVX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common tool for investors, they can often mislead, and reliance solely on them may lead to poor investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - 4D Molecular Therapeutics, Inc. (FDMT) has shown significant stock price appreciation of 42.1% over the past four weeks, with a mean price target of $31.13 suggesting a potential upside of 208.5% from the current price of $10.09 [1] Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $8.37, indicating variability among analysts [2] - The lowest price target of $16.00 suggests a 58.6% increase, while the highest target of $40.00 indicates a potential surge of 296.4% [2] - A low standard deviation among price targets reflects a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about FDMT's earnings prospects, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - Over the last 30 days, one earnings estimate has increased, leading to a 0.6% rise in the Zacks Consensus Estimate [12] - FDMT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on consensus price targets for investment decisions may not be prudent, as analysts' price targets can often be overly optimistic due to business incentives [3][8] - While price targets should not be ignored, they should be approached with skepticism, as they may not accurately predict stock price movements [10]